Table 1.

Demographics and clinical characteristics of patients with IC. Statistically significant differences (P,0.05) within age groups are shown in bold. COR and 95 % CI have been shown for significant associations only. –, Difference not statistically significant; NA, not applicable.

Variable	All cases (%)	Children	Adults	P value	COR (95% CI)
Mean age in years (range)	30.48 (0–96)	NA	NA	NA	NA
No. of males (%)	107 (59.4)	NA	NA	NA	NA
No. of children (%)	67 (37.2)	NA	NA	NA	NA
Presence of underlying risk factors in 96 medical records reviewed		NA	NA	NA	NA
Any malignancy	21 (21.9)	4 (18.2)	17 (23.0)	–	–
Haematological malignancy	6 (6.3)	2 (9.1)	4 (5.4)	–	–
CLABSI	24 (25.0)	5 (22.7)	19 (25.7)	–	–
Chronic liver disease	9 (9.4)	0 (0.0)	9 (12.2)	–	–
Complicated intra-abdominal infection	21 (21.9)	2 (9.1)	19 (25.7)	–	–
Central venous catheters	64 (66.7)	14 (63.6)	50 (67.6)	–	–
Diabetes	19 (19.8)	0 (0.0)	19 (25.7)	–	–
Dialysis	17 (17.7)	2 (9.1)	15 (20.3)	–	–
Immunosuppressed status	32 (33.3)	6 (27.3)	26 (35.1)	–	–
Neutropenia	9 (9.4)	3 (13.6)	6 (8.1)	–	–
Nosocomial IC	88 (91.6)	19 (67.9)	69 (84.1)	–	–
Pneumonia	28 (29.2)	6 (27.3)	22 (29.8)	–	–
Prior antifungal use	19 (19.8)	3 (13.6)	16 (21.6)	–	–
Sepsis	68 (70.8)	15 (68.2)	53 (71.6)	–	–
Stay in special care units	72 (75.0)	14 (63.6)	58 (78.4)	–	–
Total parenteral nutrition use	21 (21.9)	9 (40.9)	12 (16.2)	0.040	3.58 (1.25–10.23)
Transplant	2 (2.1)	0 (0.0)	2 (2.7)	–	–
Use of BLIC	44 (45.8)	3 (13.6)	41 (55.4)	0.001	0.13 (0.35–0.47)
Use of carbapenems	51 (53.1)	15 (68.2)	36 (48.6)	–	–
Use of cephalosporins	36 (37.5)	14 (63.6)	22 (29.8)	0.004	4.14 (1.52–11.26)
Use of healthcare devices	82 (85.4)	16 (72.7)	66 (89.2)	–	–
Use of vancomycin	40 (41.7)	5 (22.7)	35 (47.3)	0.040	0.33 (0.11–0.98)
Urinary tract infection	19 (19.8)	2 (9.1)	17 (23.0)	–	–
Crude mortality	50 (52.1)	10 (45.5)	40 (54.1)	–	–